853 related articles for article (PubMed ID: 26159046)
1. A single-institution retrospective analysis of outcomes for stage I-II primary mediastinal large B-cell lymphoma treated with immunochemotherapy with or without radiotherapy.
Binkley MS; Hiniker SM; Wu S; Natkunam Y; Mittra ES; Advani RH; Hoppe RT
Leuk Lymphoma; 2016; 57(3):604-8. PubMed ID: 26159046
[TBL] [Abstract][Full Text] [Related]
2. Single-institution experience in the treatment of primary mediastinal B cell lymphoma treated with immunochemotherapy in the setting of response assessment by 18fluorodeoxyglucose positron emission tomography.
Pinnix CC; Dabaja B; Ahmed MA; Chuang HH; Costelloe C; Wogan CF; Reed V; Romaguera JE; Neelapu S; Oki Y; Rodriguez MA; Fayad L; Hagemeister FB; Nastoupil L; Turturro F; Fowler N; Fanale MA; Nieto Y; Khouri IF; Ahmed S; Medeiros LJ; Davis RE; Westin J
Int J Radiat Oncol Biol Phys; 2015 May; 92(1):113-21. PubMed ID: 25863759
[TBL] [Abstract][Full Text] [Related]
3. R-CHOP versus dose-adjusted R-EPOCH in frontline management of primary mediastinal B-cell lymphoma: a multi-centre analysis.
Shah NN; Szabo A; Huntington SF; Epperla N; Reddy N; Ganguly S; Vose J; Obiozor C; Faruqi F; Kovach AE; Costa LJ; Xavier AC; Okal R; Kanate AS; Ghosh N; Kharfan-Dabaja MA; Strelec L; Hamadani M; Fenske TS; Calzada O; Cohen JB; Chavez J; Svoboda J
Br J Haematol; 2018 Feb; 180(4):534-544. PubMed ID: 29265182
[TBL] [Abstract][Full Text] [Related]
4. Outcomes of adults and children with primary mediastinal B-cell lymphoma treated with dose-adjusted EPOCH-R.
Giulino-Roth L; O'Donohue T; Chen Z; Bartlett NL; LaCasce A; Martin-Doyle W; Barth MJ; Davies K; Blum KA; Christian B; Casulo C; Smith SM; Godfrey J; Termuhlen A; Oberley MJ; Alexander S; Weitzman S; Appel B; Mizukawa B; Svoboda J; Afify Z; Pauly M; Dave H; Gardner R; Stephens DM; Zeitler WA; Forlenza C; Levine J; Williams ME; Sima JL; Bollard CM; Leonard JP
Br J Haematol; 2017 Dec; 179(5):739-747. PubMed ID: 29082519
[TBL] [Abstract][Full Text] [Related]
5. The impact of R-VACOP-B and interim FDG-PET/CT on outcome in primary mediastinal large B cell lymphoma.
Avigdor A; Sirotkin T; Kedmi M; Ribakovsy E; Berkowicz M; Davidovitz Y; Kneller A; Merkel D; Volchek Y; Davidson T; Goshen E; Apter S; Shimoni A; Ben-Bassat I; Nagler A
Ann Hematol; 2014 Aug; 93(8):1297-304. PubMed ID: 24595734
[TBL] [Abstract][Full Text] [Related]
6. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study.
Zinzani PL; Stefoni V; Finolezzi E; Brusamolino E; Cabras MG; Chiappella A; Salvi F; Rossi A; Broccoli A; Martelli M
Clin Lymphoma Myeloma; 2009 Oct; 9(5):381-5. PubMed ID: 19858058
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of dose-adjusted EPOCH plus rituximab (DA-EPOCH-R) in untreated patients with poor prognosis large B-cell lymphoma. A phase II study conducted by the Spanish PETHEMA Group.
Purroy N; Bergua J; Gallur L; Prieto J; Lopez LA; Sancho JM; García-Marco JA; Castellví J; Montes-Moreno S; Batlle A; de Villambrosia SG; Carnicero F; Ferrando-Lamana L; Piris MA; Lopez A
Br J Haematol; 2015 Apr; 169(2):188-98. PubMed ID: 25521006
[TBL] [Abstract][Full Text] [Related]
8. Dose-adjusted EPOCH-R is not superior to sequential R-CHOP/R-ICE as a frontline treatment for newly diagnosed primary mediastinal B-cell lymphoma: Results of a bi-center retrospective study.
Morgenstern Y; Aumann S; Goldschmidt N; Gatt ME; Nachmias B; Horowitz NA
Cancer Med; 2021 Dec; 10(24):8866-8875. PubMed ID: 34816617
[TBL] [Abstract][Full Text] [Related]
9. Favorable outcome of primary mediastinal large B-cell lymphoma patients treated with sequential RCHOP-RICE regimen without radiotherapy.
Goldschmidt N; Kleinstern G; Orevi M; Paltiel O; Ben-Yehuda D; Gural A; Libster D; Lavie D; Gatt ME
Cancer Chemother Pharmacol; 2016 May; 77(5):1053-60. PubMed ID: 27056383
[TBL] [Abstract][Full Text] [Related]
10. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factors in 41 consecutive Asian patients.
Tai WM; Quah D; Yap SP; Tan SH; Tang T; Tay KW; Koo YX; Tao M; Quek R; Lim ST
Leuk Lymphoma; 2011 Apr; 52(4):604-12. PubMed ID: 21261504
[TBL] [Abstract][Full Text] [Related]
11. Real world experience of R-CHOP with or without consolidative radiotherapy vs DA-EPOCH-R in the first-line treatment of primary mediastinal B-cell lymphoma.
Chan EHL; Koh LP; Lee J; De Mel S; Jeyasekharan A; Liu X; Tang T; Lim ST; Tao M; Quek R; Farid Bin Harunal Ras M; Lee YS; Diong C; Tan D; Kim SJ; Chee YL; Poon LMM
Cancer Med; 2019 Aug; 8(10):4626-4632. PubMed ID: 31264808
[TBL] [Abstract][Full Text] [Related]
12. Early treatment intensification with R-ICE and 90Y-ibritumomab tiuxetan (Zevalin)-BEAM stem cell transplantation in patients with high-risk diffuse large B-cell lymphoma patients and positive interim PET after 4 cycles of R-CHOP-14.
Hertzberg M; Gandhi MK; Trotman J; Butcher B; Taper J; Johnston A; Gill D; Ho SJ; Cull G; Fay K; Chong G; Grigg A; Lewis ID; Milliken S; Renwick W; Hahn U; Filshie R; Kannourakis G; Watson AM; Warburton P; Wirth A; Seymour JF; Hofman MS; Hicks RJ;
Haematologica; 2017 Feb; 102(2):356-363. PubMed ID: 28143954
[TBL] [Abstract][Full Text] [Related]
13. Complications Associated With Dose-adjusted EPOCH-rituximab Therapy for Non-Hodgkin Lymphoma.
David RJ; Baran A; Loh KP; Casulo C; Barr PM; Friedberg JW; Reagan PM
Clin Lymphoma Myeloma Leuk; 2018 Dec; 18(12):781-787. PubMed ID: 30262330
[TBL] [Abstract][Full Text] [Related]
14. Favorable outcome of primary mediastinal large B-cell lymphoma in a single institution: the British Columbia experience.
Savage KJ; Al-Rajhi N; Voss N; Paltiel C; Klasa R; Gascoyne RD; Connors JM
Ann Oncol; 2006 Jan; 17(1):123-30. PubMed ID: 16236753
[TBL] [Abstract][Full Text] [Related]
15. End-of-treatment and serial PET imaging in primary mediastinal B-cell lymphoma following dose-adjusted EPOCH-R: a paradigm shift in clinical decision making.
Melani C; Advani R; Roschewski M; Walters KM; Chen CC; Baratto L; Ahlman MA; Miljkovic MD; Steinberg SM; Lam J; Shovlin M; Dunleavy K; Pittaluga S; Jaffe ES; Wilson WH
Haematologica; 2018 Aug; 103(8):1337-1344. PubMed ID: 29748435
[TBL] [Abstract][Full Text] [Related]
16. Second cancer incidence in primary mediastinal B-cell lymphoma treated with methotrexate with leucovorin rescue, doxorubicin, cyclophosphamide, vincristine, prednisone, and bleomycin regimen with or without rituximab and mediastinal radiotherapy: Results from a monoinstitutional cohort analysis of long-term survivors.
De Sanctis V; Alfò M; Di Rocco A; Ansuinelli M; Russo E; Osti MF; Valeriani M; Minniti G; Grapulin L; Musio D; Bracci S; Spagnoli A; Moleti ML; Tombolini V; Martelli M
Hematol Oncol; 2017 Dec; 35(4):554-560. PubMed ID: 28078727
[TBL] [Abstract][Full Text] [Related]
17. Strikingly high false positivity of surveillance FDG-PET/CT scanning among patients with diffuse large cell lymphoma in the rituximab era.
Avivi I; Zilberlicht A; Dann EJ; Leiba R; Faibish T; Rowe JM; Bar-Shalom R
Am J Hematol; 2013 May; 88(5):400-5. PubMed ID: 23423884
[TBL] [Abstract][Full Text] [Related]
18. Dose-adjusted EPOCH-rituximab therapy in primary mediastinal B-cell lymphoma.
Dunleavy K; Pittaluga S; Maeda LS; Advani R; Chen CC; Hessler J; Steinberg SM; Grant C; Wright G; Varma G; Staudt LM; Jaffe ES; Wilson WH
N Engl J Med; 2013 Apr; 368(15):1408-16. PubMed ID: 23574119
[TBL] [Abstract][Full Text] [Related]
19. Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study.
Chiappella A; Martelli M; Angelucci E; Brusamolino E; Evangelista A; Carella AM; Stelitano C; Rossi G; Balzarotti M; Merli F; Gaidano G; Pavone V; Rigacci L; Zaja F; D'Arco A; Cascavilla N; Russo E; Castellino A; Gotti M; Congiu AG; Cabras MG; Tucci A; Agostinelli C; Ciccone G; Pileri SA; Vitolo U
Lancet Oncol; 2017 Aug; 18(8):1076-1088. PubMed ID: 28668386
[TBL] [Abstract][Full Text] [Related]
20. Results of a prospective phase II trial evaluating interim positron emission tomography-guided high dose therapy for poor prognosis diffuse large B-cell lymphoma.
Stewart DA; Kloiber R; Owen C; Bahlis NJ; Duggan P; Mansoor A; Bence-Bruckler I
Leuk Lymphoma; 2014 Sep; 55(9):2064-70. PubMed ID: 24188476
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
